A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.9
2 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 52 (final count)
- Started
- Feb 10, 2023
- Main results expected
- Apr 27, 2025
- Fully finished
- Dec 31, 2027
- Results posted
- Jun 12, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphoma
Measured over: Up to approximately 7 months
Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE)
Measured over: Up to approximately 7 months
Number of Participants With Abnormal Changes From Baseline in Laboratory Measurements
Measured over: Up to approximately 7 months
Number of Participants With Abnormal Changes From Baseline in Vital Sign Measurements (Blood Pressure)
Measured over: Up to approximately 7 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05673785 · record last updated 2026-06-12 · checked 2026-11-09 15:47 UTC